172@29@17@249!~!172@29@0@53!~!|news|business|moneycontrol-research|prospects-for-us-business-and-leadership-in-respiratory-therapies-make-cipla-attractive-5671191.html!~!|controller|infinite_scroll_article.php
App
Moneycontrol AppAndroid AppiOS AppiPad AppAndroid TabBlackberryWindows AppWindows Tab
Subscription
Specials
Stocks
Feedback
Log In
Sign Up
Moneycontrol
Financial Freedom Offer: Subscribe to Moneycontrol Pro and grab benefits worth ₹15,000/-
you are here: HomeNewsBusinessMoneycontrol Research
  
  1
Last Updated Last Updated : Aug 10, 2020 08:15 AM IST | Source: Moneycontrol.com

Prospects for US business and leadership in respiratory therapies make Cipla attractive

Cipla's US revenues clocked a sequential improvement to about $135 million, backed by a ramp-up in the generic version of gProventil HFA

Anubhav Sahu @anubhavsays

To view the full content of this article, you have to be a Pro:

  • Not a Moneycontrol Pro subscriber yet?

Subscribe to Moneycontrol Pro:

What's included:

  • Ad free experience across Platforms
  • 230+ exclusive stories per month
  • Sharpest Opinions & Actionable Insights
  • Exclusive Research & Expert Technical Analysis
  • Daily Newsletter
  • 20+ Technical Picks every week
  • Recovery Tracker
  • Exclusive webinars on varied topics
  • Weekly wrap up and much more!!!
Subscribe to Annual plan of PRO at Rs. 365/- for the first year and unlock offers worth Rs. 15,000/- »